WilmerHale Webinar: Deciphering the New FDA Reform Legislation - What the FDA Amendments Act of 2007 Means for Research-Based Pharmaceutical Companies (Session One)

WilmerHale Webinar: Deciphering the New FDA Reform Legislation - What the FDA Amendments Act of 2007 Means for Research-Based Pharmaceutical Companies (Session One)

Speaking Engagement
This WilmerHale webinar series is designed to provide pharmaceutical companies with a detailed overview of the new Food & Drug Administration Amendments Act of 2007, a forecast of its impact on all aspects of regulatory compliance and product development, as well as practical tips to prepare for implementation of the new regulatory requirements. This first session will offer an overview of the new drug provisions of FDAAA and will also address the competitive impact of FDAAA on exclusivities and the Citizen Petition process.

Read More About the Event

Speakers

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.